# Diabetes Research Hub — Monitor Report

**Run date:** 2026-04-29
**Monitor type:** Automated scheduled review (read-only)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`
**Comparison windows:** vs. 2026-04-28 (1d) and 2026-04-22 (7d) snapshots

---

## File System Status

All four primary data feeds are present and current.

| File | Last modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-04-29 07:05 | 0d | Current |
| `clinical_trials_latest.json` | 2026-04-29 07:04 | 0d | Current (775 trials) |
| `clinical_trials_summary.md` | 2026-04-29 07:04 | 0d | Current |
| `pubmed_recent_latest.json` | 2026-04-29 07:05 | 0d | Current (155 papers) |
| `pubmed_recent_summary.md` | 2026-04-29 07:05 | 0d | Current |
| `literature_gap_report.md` | 2026-04-28 08:11 | 1d | Current |
| `literature_gap_data.json` | 2026-04-20 10:35 | 8.7d | **Stale** — gap matrix is regenerated weekly; due for refresh |
| `agent_state.json` | 2026-04-28 08:13 | 1d | Current |

The hub_monitor_report.md flags 501 result files older than 14 days (was 499 yesterday); these are dated snapshot files (e.g., `clinical_trials_snapshot_2026-03-15.json`) intended as historical record — not staleness. No action needed.

---

## Clinical Trial Changes

**Snapshot:** 775 unique trials today (up from 773 yesterday, 769 seven days ago).

### New trials since yesterday (2)
- **NCT04831697** — Medical College of Wisconsin — N/A — COMPLETED — *Intervention to Improve Diabetes Outcomes in Older African American Women With Mild Cognitive Impairment* (entered the active pull because results were posted 2026-04-28).
- **NCT07554443** — RxFunction Inc. — N/A — NOT_YET_RECRUITING — *Wearable Sensory Prosthesis to Improve Coordination, Walking, and Physical Activity* (diabetic peripheral neuropathy).

### Status changes (1d): none
### Newly posted results (1d): none beyond the NCT04831697 entry above

### Status changes (7-day window) — 3 (carry-over from prior reports)
- **NCT07400588** — Aleniglipron Phase 2 in T2DM: RECRUITING → ACTIVE_NOT_RECRUITING
- **NCT06993792** — Eli Lilly orforglipron master protocol: RECRUITING → ACTIVE_NOT_RECRUITING (Phase 3)
- **NCT04061746** — MSC cellular therapy for T1D: RECRUITING → ACTIVE_NOT_RECRUITING

### Recently posted results (last 30 days) — 16 total
The two highest-priority Phase 3 postings remain:

| NCT | Sponsor | Phase | Posted | Trial |
|---|---|---|---|---|
| NCT05649137 | Novo Nordisk | Phase 3 | 2026-04-27 | Semaglutide in excess weight + T2D |
| NCT05971940 | Eli Lilly | Phase 3 | 2026-04-22 | Orforglipron (LY3502970) in T2D adults |
| NCT05727579 | Amsterdam UMC | Phase 4 | 2026-04-15 | Sodium intake × ertugliflozin renal effects |
| NCT01633177 | Brigham & Women's | Phase 3 | 2026-04-03 | Vitamin D + ω-3 for diabetes prevention |
| NCT05144984 | Novo Nordisk | Phase 2 | 2026-04-09 | Semaglutide + cagrilintide combo |

Both Phase 3 results (Novo Nordisk semaglutide + Lilly orforglipron) were flagged for analyst review yesterday and remain open action items.

### Phase 3 RECRUITING — 44 active
No change in count vs. yesterday. Most strategically important active recruiters (unchanged):
- **NCT07548996 / NCT07258394** — Dimethyl Fumarate in T1D (β-cell preservation, repurposing signal)
- **NCT07088068** — Sanofi teplizumab Phase 3 vs placebo (PETITE-T1D follow-on)
- **NCT06832410** — Vertex VX-880/zimislecel Phase 3 in T1D
- **NCT07222332 / NCT07222137** — Eli Lilly baricitinib Phase 3 for β-cell preservation (T1D children/adults)

### Key-organization snapshot (unchanged from 2026-04-28)
- **Vertex:** 3 trials — VX-880 Phase 3 (RECRUITING) and VX-264 Phase 1/2 (ACTIVE_NOT_RECRUITING).
- **Eli Lilly:** 27 trials — orforglipron, tirzepatide, retatrutide, baricitinib pipelines.
- **Novo Nordisk:** 23 trials — CagriSema Phase 3 expansion, weekly insulin icodec, oral semaglutide.
- **Sana Biotechnology:** 0 diabetes trials in current pull.

---

## PubMed Highlights

**155 unique papers** in 30-day rolling window (search corpus capped at 10/domain). 24 papers added since yesterday, 24 dropped (rolling-window churn).

### Cross-domain new papers (highest value — 2 net-new)
| PMID | Domains | Title (truncated) |
|---|---|---|
| 42046530 | Diabetes Biomarker, Diabetes Multi-Omics | Mechanisms of Mulberry Leaf Extracts Ameliorating Inflammation and Fibrosis in NAFLD |
| 42046753 | T1D Immunotherapy, Closed Loop AP | Effect of breaking up sitting with regular active breaks on glucose management and vascular function |

### All cross-domain papers in current 30-day corpus (6 total)
| PMID | Domains | Title (truncated) |
|---|---|---|
| 41297910 | Key Therapy: orforglipron, retatrutide, CagriSema | Engineered nutrient-stimulated hormonal multi-agonists |
| 42038260 | Diabetes Microbiome, Diabetes Multi-Omics | Pathology, molecular mechanisms, and intervention strategies of cognitive dysfunction in diabetes |
| 42032109 | Diabetes Gene Therapy, Diabetes Epigenetics | Cell-specific DNA methylation in human α and β cells in T2D |
| 42023429 | T1D Immunotherapy, Diabetes Gene Therapy | CRISPR-based β-cell replacement and Treg modulation |
| 42046530 | Diabetes Biomarker, Diabetes Multi-Omics | Mulberry leaf extracts in NAFLD (NEW today) |
| 42046753 | T1D Immunotherapy, Closed Loop AP | Active breaks effect on glucose and vascular function (NEW today) |

PMID 41297910 remains the highest-priority unread paper (only paper triangulating all three Tier-3 multi-agonist therapies).

### Notable new papers added today (subset of 24)
- **PMID 42049287** — *Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled GLP-1 trials* (T2D GLP-1 New) — directly relevant to ongoing safety questions about NAION/GLP-1 class.
- **PMID 42048049** — *Evaluating once-weekly insulin efsitora alfa for adults with T2D* (Key Therapy: icodec) — adds to the weekly-insulin pipeline tracker.
- **PMID 42046405** — *Effects of Dapagliflozin on Cardiovascular Outcomes in T2D at Risk* (Key Therapy: dapagliflozin) — relevant to generic-dapagliflozin equity narrative.
- **PMID 42045947** — *Autoimmune Phenomena and New-Onset T1D Following SARS-CoV-2 Vaccination: A Perspective* (T1D Immunotherapy).
- **PMID 42048939** — *Deep learning-based early prediction of GDM through first-trimester data* (Diabetes AI/ML) — fits Tier-1 #1 (multi-omics biomarker integration).

### Key-therapy mention counts (last 30d, unchanged from yesterday)
| Therapy | Title/abstract hits |
|---|---|
| dapagliflozin | 5 |
| orforglipron | 3 |
| teplizumab | 1 |
| retatrutide | 1 |
| CagriSema | 0 |
| baricitinib | 0 |
| zimislecel | 0 |

zimislecel is conspicuously absent from the 30-day corpus despite Vertex's two active Phase 3 trials — likely a search-term issue (papers may use "VX-880"); worth tuning the alert query.

### Domain volume
Highest activity domains today: AI/ML (179 search hits), GLP-1 New (157), Biomarker (146), Microbiome (142). Lowest: GLP-1 Pharmacogenomics (0), LADA (4), Drug Repurposing (4) — these remain genuinely thin areas.

---

## Gap Analysis Summary

`literature_gap_data.json` is now 8.7 days old (over the 7-day refresh cadence). Top 5 ranked gaps (gap_score = 100):

| Rank | Domain pair | Joint pubs | Notes |
|---|---|---|---|
| 1 | Beta Cell Regen × Health Equity | 0 | Equity analysis of regenerative cell therapies entirely missing |
| 2 | Insulin Resistance × Islet Transplant | 1 | IR in transplant recipients affects graft survival but barely studied |
| 3 | Islet Transplant × GWAS / Polygenic | 0 | Methodologically distinct; lower priority |
| 4 | Islet Transplant × Personalized Nutr | 0 | Methodologically distinct |
| 5 | Islet Transplant × Drug Repurposing | 0 | Repurposed immunosuppressants for islet protection — high computational fit |

### Tier-1 alignment (per RESEARCH_DOCTRINE.md) — unchanged from 2026-04-28
- **Drug Repurposing (Tier 1 #4):** four 100-score intersections (Islet Transplant, Glucokinase, Health Equity, LADA).
- **Health Equity (Tier 1 #6):** five separate 100-score intersections — a cross-domain equity synthesis would close multiple gaps simultaneously.
- **Literature Synthesis (Tier 1 #2):** Gene Therapy × LADA, Personalized Nutr × LADA — both 100.

The new cross-domain paper PMID 42032109 (Gene Therapy × Epigenetics, α/β cell methylation) provides emerging evidence for Tier-1 #1 (Multi-Omics Biomarker Integration).

---

## Breaking News (web search, last 7 days)

No new high-significance items beyond what was already logged on 2026-04-28. Standing items:

1. **FDA expansion of Tzield (teplizumab) to children ≥1 year (2026-04-22, Sanofi)** — sBLA approval extends T1D delay-of-onset indication from age 8+ down to age 1+, supported by 1-year PETITE-T1D Phase 4 data. Direct read-across to NCT07088068. *Logged but tracker entry still pending.*
2. **Eli Lilly Foundayo (orforglipron) FDA approval (2026-04-01)** + Phase 3 results posting (NCT05971940, 2026-04-22). *Logged but tracker entry still pending.*
3. **Generic dapagliflozin tablets FDA approval (2026-04-07)** — relevant to Health Equity gap analysis. *Logged but tracker entry still pending.*

Searches for "diabetes breakthrough 2026" and "FDA diabetes approval 2026" surfaced no further actionable items in the 2026-04-22 → 2026-04-29 window. Vertex zimislecel Phase 3 (NCT06832410) remains in enrollment with no new public read-out since the prior NEJM publication / ADA 85th data.

---

## Recommended Actions

1. **Refresh literature gap analysis (overdue).** `literature_gap_data.json` is now 8.7 days old, past the weekly cadence. Run: `python project1_literature_gap_analysis.py` to capture the +24 new papers added since yesterday and the cumulative additions since 2026-04-20.
2. **Tracker still missing the three FDA-action entries** flagged on 2026-04-28 (Tzield pediatric expansion, Foundayo approval, generic dapagliflozin) plus the two Phase 3 result postings (NCT05649137, NCT05971940). Update Diabetes_Research_Tracker.xlsx and cite at Bronze/Silver evidence per Doctrine until peer-reviewed analyses publish.
3. **Tune zimislecel alert query.** Add "VX-880" as a synonym in `baseline_pubmed_alerts.py`; current corpus shows zero hits despite active Phase 3 enrollment, almost certainly a terminology mismatch.
4. **Read the two new cross-domain papers added today** — PMID 42046530 (Biomarker × Multi-Omics) and PMID 42046753 (T1D Immunotherapy × Closed Loop AP). The latter is a behavioral/AP intersection rarely seen in the corpus.
5. **PMID 42049287 (NAION incidence in GLP-1 placebo-controlled trials)** — read; aggregates safety signal across the GLP-1 class. Relevant to tracker entries for orforglipron, semaglutide, and tirzepatide pipelines.
6. **Carry-over actions from 2026-04-28** still open: read PMID 41297910 (multi-agonist precision targeting); read PMID 42032109 (α/β cell methylation); pursue Drug Repurposing × Islet Transplant gap; pursue Health Equity gap synthesis; track Sanofi teplizumab Phase 3 NCT07088068; populate "Notable Trials to Watch" in clinical_trials_summary.md.
7. **No script reruns required for trial / PubMed feeds** — both ran today at 07:04–07:05 and are fresh.

---

## Sources

- [Sanofi — Tzield approved in young children (2026-04-22)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650)
- [FDA expands teplizumab approval — Pharmacy Times](https://www.pharmacytimes.com/view/fda-expands-teplizumab-mzwv-approval-to-delay-stage-3-type-1-diabetes-in-children-as-young-as-1-year)
- [FDA approves Lilly's Foundayo (orforglipron)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
- [FDA approves first generic dapagliflozin — AJMC](https://www.ajmc.com/view/fda-approves-first-generic-dapagliflozin-to-reduce-hf-hospitalization-risk-in-type-2-diabetes)
- [Vertex zimislecel positive data at ADA 85th](https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes)
- [VX-880 NCT06832410 (Phase 3)](https://clinicaltrials.gov/study/NCT06832410)

---

*Generated by automated diabetes-hub-monitor task — 2026-04-29*
